Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Dataset wrap
Nametu
Rowcaps
Rows 7-8:Show the identification of a split tumor when it was first identified as split (fragmented). In this example, TULNKID = "tumor T04 " splits into 2 tumors TULNKID = "(T04.1" and TULNKID = ", T04.2" with TUGRPID = "T04". ); TUGRPID = "T04" provides traceability and links the split tumor to its parent recordsrecord.
Row 9: Shows the identification of a merged tumor when it was first identified as merged (coalesced). In this example, TULNKID = "tumors T02 " and TULNKID = " T03 " merged into tumor T02/T03; TULNKID = "T02/T03" . The TULNKID is a combination of the child tumors and therefore provides the traceability back to the child tumors.
Dataset2
RowSTUDYIDDOMAINUSUBJIDTUSEQTUGRPIDTUREFIDTUSPIDTULNKIDTUTESTCDTUTESTTUORRESTUSTRESCTULOCTUMETHODTUEVALEPOCHVISITNUMVISITTUDTCTUDY
1EX22222TU900021
IMG-00001TRG-SCR-01T01TUMIDENTTumor IdentificationTARGETTARGETLUNG, RIGHT MIDDLE LOBECT SCANINVESTIGATORSCREEN1SCREENING2007-01-011
2EX22222TU900022
IMG-00001TRG-SCR-02T02TUMIDENTTumor IdentificationTARGETTARGETLUNG, LEFT LOWER LOBECT SCANINVESTIGATORSCREEN1SCREENING2007-01-011
3EX22222TU900023
IMG-00001TRG-SCR-03T03TUMIDENTTumor IdentificationTARGETTARGETLUNG, LEFT LOWER LOBECT SCANINVESTIGATORSCREEN1SCREENING2007-01-011
4EX22222TU900024
IMG-00001TRG-SCR-04T04TUMIDENTTumor IdentificationTARGETTARGETKIDNEY, UPPER LOBECT SCANINVESTIGATORSCREEN1SCREENING2007-01-011
5EX22222TU900025
IMG-00001NTG-SCR-01NT01TUMIDENTTumor IdentificationNON-TARGETNON-TARGETLUNGCT SCANINVESTIGATORSCREEN1SCREENING2007-01-011
6EX22222TU900026
IMG-00001NTG-SCR-02NT02TUMIDENTTumor IdentificationNON-TARGETNON-TARGETLIVERCT SCANINVESTIGATORSCREEN1SCREENING2007-01-011
7EX22222TU900027T04IMG-00002TRG-W16-07T04.1TUSPLITTumor SplitTARGETTARGETKIDNEY, UPPER LOBECT SCANINVESTIGATORTREATMENT5WEEK 162007-04-24112
8EX22222TU900028T04IMG-00002TRG-W16-08T04.2TUSPLITTumor SplitTARGETTARGETKIDNEY, UPPER LOBECT SCANINVESTIGATORTREATMENT5WEEK 162007-04-24112
9EX22222TU900029
IMG-00003TRG-W28-07T02/T03TUMERGETumor MergedTARGETTARGETLUNG, LEFT LOWER LOBECT SCANINVESTIGATORTREATMENT7WEEK 242009-06-19168
10EX22222TU9000210
IMG-00004NWT-W32-01NEW01TUMIDENTTumor IdentificationNEWNEWLIVERCT SCANINVESTIGATORTREATMENT9WEEK 322009-08-14224

...

4.3.3 TR Domain Model

The following tr.xpt table shows table shows the terminology used to implement RECIST implement RECIST 1.1 in the TR domain. This 1 in the TR domain. This example represents a situation where a result was not provided because the scan was not performed.

...

4.8.3 TR Domain Model

The following table shows table shows the terminology used to implement RECIST implement RECIST 1.1 in the TR domain1 in the TR domain. This example shows the data for 1 subject collected at the screening, week 12, and week 24 visits.  This This example also shows that the tumor state for the non-target in the pleural cavity is an assessment of the pleural effusion. Scintigraphy of the bone was not required at every disease assessment per protocol.  The The image identifier is in TRREFID. 

...

Dataset wrap
Nametr
Rowcaps
Rows 1-4: Show the measurements of the "target tumor (R-T01" target tumor ) in the "LIVER" liver and the assessments of the 2 non-target lesions "(R-NT01" and ", R-NT02" ) in the "BONE" and "PLEURAL CAVITY" bone and pleural cavity at screening.  
Rows 5-11: Show the measurement of the "target tumor (R-T01" target tumor ) and the tumor state of the "1 non-target tumor (R-NT02" non-target ) in the "PLEURAL CAVITY" pleural cavity at week 12. In the Per protocol, "SCINTIGRAPHY" is scintigraphy was only to be performed every 6 months or in order to verify a CR (Complete Response). Therefore, the "SCINTIGRAPHY" of "complete response; therefore, scintigraphy of non-target R-NT01 " non-target in the "BONE" bone was not performed at week 12 (TRSTAT = "NOT DONE" and TRREASND = "SCAN NOT PERFORMED").
Rows 12-18: Show that, at week 24, the "target lesion (R-T01" target lesion ) was absent (i.e., DIAMETER = "0") and the ; non-targets R-"NT01 " and " R-NT02 " in the "BONE" and "PLEURAL CAVITY" also were absent (TRTESTCD = "TUMSTATE" with TRORRES = "ABSENT"). The "SCINTIGRAPHY" Scintigraphy was performed in order to verify the Overall Response overall response of CR (Complete Response).
Dataset2
RowSTUDYIDDOMAINUSUBJIDTRSEQTRGRPIDTRREFIDTRLNKGRPTRLNKIDTRTESTCDTRTESTTRORRESTRORRESUTRSTRESCTRSTRESNTRSTRESUTRSTATTRREASNDTRNAMTRMETHODTREVALTREVALIDEPOCHVISITNUMVISITTRDTCTRDY
1EX88888TR900081TARGETIMG-00001R-A1R-T01LDIAMLongest Diameter17mm1717mm

VENDOR1CT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
2EX88888TR900082TARGET

R-A1


SUMDIAMSum of Diameter17mm1717mm

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
3EX88888TR900083NON-TARGETIMG-00002R-A1R-NT01TUMSTATETumor StatePRESENT
PRESENT



VENDOR1SCINTIGRAPHYINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-01-3
4EX88888TR900084NON-TARGETIMG-00001

R-A1

R-NT02TUMSTATETumor StatePRESENT
PRESENT



VENDOR1CT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
5EX88888TR900085TARGETIMG-00004R-A2R-T01LDIAMLongest Diameter7mm77mm

VENDOR1CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
6EX88888TR900086TARGET
R-A2
SUMDIAMSum of Diameter7mm77mm

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

7EX88888TR900087TARGET
R-A2
ACNSDAbsolute Change From Nadir in Sum of Diameter-10mm-10-10mm

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

8EX88888TR900088TARGET
R-A2
PCBSDPercent Change From Baseline in Sum of Diameter-59%-59-59%

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

9EX88888TR900089TARGET
R-A2
PCNSDPercent Change From Nadir in Sum of Diameter-59%-59-59%

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

10EX88888TR9000810NON-TARGET
R-A2R-NT01TUMSTATETumor State




NOT DONESCAN NOT PERFORMEDVENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

11EX88888TR9000811NON-TARGETIMG-00004R-A2R-NT02TUMSTATETumor StatePRESENT
PRESENT



VENDOR1CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
12EX88888TR9000812TARGETIMG-00005R-A3R-T01LDIAMLongest Diameter0mm00mm

VENDOR1CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171
13EX88888TR9000813TARGET
R-A3
SUMDIAMSum of Diameter0mm00mm

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

14EX88888TR9000814TARGET
R-A3
ACNSDAbsolute Change From Nadir in Sum of Diameter-17mm-17-17mm

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

15EX88888TR9000815TARGET
R-A3
PCBSDPercent Change From Baseline in Sum of Diameter-100%-100-100%

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

16EX88888TR9000816TARGET
R-A3
PCNSDPercent Change From Nadir in Sum of Diameter-100%-100-100%

VENDOR1
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

17EX88888TR9000817NON-TARGETIMG-00006R-A3R-NT01TUMSTATETumor StateABSENT
ABSENT



VENDOR1SCINTIGRAPHYINDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-24172
18EX88888TR9000818NON-TARGETIMG-00005R-A3R-NT02TUMSTATETumor StateABSENT
ABSENT



VENDOR1CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171

4.8.4 PR Domain Model

The  pr.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in 1 in the PR domainPR domain. This example shows the data for one 1 subject collected at the screening, week 12, and week 24 visits.  Per Per protocol, non-target lesions in the "BONE" are assessed using "SCINTIGRAPHY" bone were assessed using scintigraphy as the primary method of assessment for RECIST 1.1. Correlative imaging is was used in addition to the primary method for the RECIST 1.1 evaluation in order to more closely assess the bone lesion(s). The primary method of assessment (i.e., scintigraphy) is represented in TU and TR domains along with assessment results. Correlative imaging (e.g., MRI of the FEMURfemur) is represented only in the PR domain. Scintigraphy and the correlative imaging are were not required at every disease assessment per protocol. However, often times the correlative imaging is performed at every disease assessment timepoint because the same scans cover lesions that are assessed at every disease assessment timepoint. The image identifier is in PRREFID.

Dataset wrap
Namepr
Rowcaps
Rows 1-3: Show the scans performed at screening. The CT SCAN scan and SCINTIGRAPHY scintigraphy are the primary methods used to assess the target and non-target lesion for RECIST 1.1 and ; the results are in TU and TR. Row 3 shows the correlative imaging (i.e., MRI) of the bone lesion in the FEMURfemur
Rows 4-6: Show that the CT scan was performed (PROCCUR = "Y") and that the scintigraphy and MRI were not performed (PROCCUR = "N") at week 12.
Rows 7-9: Show the scans performed at week 24.
Dataset2
RowSTUDYIDDOMAINUSUBJIDPRSEQPRREFIDPRLNKGRPPRTRTPRLOCPRPRESPPROCCUREPOCHVISITNUMVISITPRSTDTCPRSTDY
1EX88888PR900081IMG-00001A1CT SCANMULTIPLEY

Y

SCREEN10SCREENING2010-01-01-3
2EX88888PR900082IMG-00002A1SCINTIGRAPHYBONEYYSCREEN10SCREENING2010-01-02-2
3EX88888PR900083IMG-00003A1MRIFEMURYYSCREEN10SCREENING2010-01-03-1
4EX88888PR900084IMG-00004A2CT SCANMULTIPLEYYTREATMENT20WEEK 122010-03-2985
5EX88888PR900085
A2SCINTIGRAPHYBONEYNTREATMENT20WEEK 12

6EX88888PR900086
A2MRIFEMURYNTREATMENT20WEEK 12

7EX88888PR900087IMG-00005A3CT SCANMULTIPLEYYTREATMENT30WEEK 242010-06-24172
8EX88888PR900088IMG-00006A3SCINTIGRAPHYBONEYYTREATMENT30WEEK 242010-06-23171
9EX88888PR900089IMG-00007A3MRIFEMURYYTREATMENT30WEEK 242010-06-25173

The following supppr.xpt table below shows the data to represent the multiple locations covered by the CT SCAN. The Anatomical Location 1 and Anatomical Location 2 anatomical location supplemental qualifiers (QNAM = "PRLOC1" and QNAM = "PRLOC2") supplemental qualifiers   are used and controlled terminology is available (LOC).

Dataset wrap
Namesupppr
Rowcaps
Rows 1-2: Show the 2 locations of the CT SCAN scan for PRSEQ = "1" where QNAM = "PRLOC1" with QVAL = "CHEST" and QNAM = "PRLOC2" with QVAL = "ABDOMEN".
Rows 3-6: Show the 2 locations of the CT SCAN scan for PRSEQ 4 and 7.
Dataset2
RowSTUDYIDRDOMAINUSUBJIDIDVARIDVARVALQNAMQLABELQVALQORIG
1EX88888PR90008PRSEQ1PRLOC1Anatomical Location 1CHESTeDC
2EX88888PR90008PRSEQ1PRLOC2

Anatomical Location 2

ABDOMENeDC
3EX88888PR90008PRSEQ4PRLOC1

Anatomical Location 1

CHESTeDC
4EX88888PR90008PRSEQ4PRLOC2

Anatomical Location 2

ABDOMENeDC
5EX88888PR90008PRSEQ7PRLOC1

Anatomical Location 1

CHESTeDC
6EX88888PR90008PRSEQ7PRLOC2

Anatomical Location 2

ABDOMENeDC

4.9 Example 9 Example 9: No Evidence of Disease at Baseline

RECIST 1.1 example to show This example shows an assessment where the independent radiologist found no evidence of disease at baseline. 

4.9.1 RS Domain Model

The rs.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in 1 in the RS domainRS domain. This example shows the data collected for one 1 subject at screening for which ; the independent radiologist found no evidence of disease at baseline (RSSTRESC = "NED"). This a rare case where a response assessment would be recorded based on the screening assessment. RSCAT = "PROTOCOL DEFINED RESPONSE CRITERIA" was used to indicate that this result is not based on RECIST 1.1. In this example, there are no data in TU or TR, because no tumors were identified.

Dataset wrap
Namers
Dataset2
RowSTUDYIDDOMAINUSUBJIDRSSEQRSLNKGRPRSTESTCDRSTESTRSCATRSORRESRSSTRESCRSNAMRSEVALRSEVALIDEPOCHVISITNUMVISITRSDTCRSDY
1EX99999RS900091A1OVRLRESPOverall ResponsePROTOCOL DEFINED RESPONSE CRITERIANEDNEDRADIOL. INC.INDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-03-291

4.10 Example 10: Enlargement from Nadir of a Single Non-

...

target 

This example shows

...

RECIST 1.1 example to show response (RS) data and the underlying tumor identification (TU) and tumor results (TR) data based on an independent independent assessment. This example shows the situation where  In this situation, enlargement from nadir of a single Nonnon-target lesion/tumor does not necessarily mean necessarily mean that the Nonnon-Target Response is PDtarget response is progressive disease.

4.10.1 RS Domain Model

The rs.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in 1 in the RS domainRS domain. This example shows the data for one 1 subject collected at the week 12 and a subsequent 12-week follow-up visit. 

Dataset wrap
Rowcaps
Rows 1-3: Show the Target Response target response (RSTESTCD = "TRGRESP"), Nonnon-Target Response target response (RSTESTCD = "NTRGRESP"), and Overall Response overall response (RSTESTCD = "OVRLRESP") at week 12. The Target Response target response of PR (Partial Response) is based on the Percent Change From Baseline in Sum of Diameter percent change from baseline in sum of diameter (PCBSD) of -59%. The Nonnon-Target Response target response of SD (Stable Disease) is based on the judgement assessment of the non-target lesions/tumors taken collectively. In this case at week 12, one 1 of the non-targets is absent and one 1 of the non-targets has enlarged from nadir. The Overall Response overall response is PR (Partial Response).
Rows 4-6: Show the Target Response (RSTESTCD = "TRGRESP"), Non-Target Response (RSTESTCD = "NTRGRESP") and Overall Response (RSTESTCD = "OVRLRESP") target response, non-target response, and overall response at week 24. The Target Response target response of CR (Complete Response) is based on the Percent Change From Baseline in Sum of Diameter ( PCBSD ) of -100%. The Nonnon-Target Response target response of SD (Stable Disease) is based on the judgement on  assessment of the non-target lesions/tumors taken collectively. In this case at week 24, one 1 of the non-targets is absent and one 1 of the non-targets is still present. The Overall Response overall response is PR (Partial Response).
Dataset2
RowSTUDYIDDOMAINUSUBJIDRSSEQRSLNKGRPRSTESTCDRSTESTRSCATRSORRESRSSTRESCRSNAMRSEVALRSEVALIDEPOCHVISITNUMVISITRSDTCRSDY
1EX01010RS900101
TRGRESPTarget ResponseRECIST 1.1PRPRRADIOL. INC.INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
2EX01010RS900102
NTRGRESPNon-Target ResponseRECIST 1.1SDSDRADIOL. INC.INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
3EX01010RS900103R-A2OVRLRESPOverall ResponseRECIST 1.1PRPRRADIOL. INC.INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
4EX01010RS900104
TRGRESPTarget ResponseRECIST 1.1CRCRRADIOL. INC.INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171
5EX01010RS900105
NRGRESPNon-Target ResponseRECIST 1.1SDSDRADIOL. INC.INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171
6EX01010RS900106R-A3OVRLRESPOverall ResponseRECIST 1.1PRPRRADIOL. INC.INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171

4.10.2 TU Domain Model

The  tu.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in the TU domain1 in the TU domain. This example shows the data for one 1 subject with target with target and non-target tumors identified at screening. The subject has 1 target lesion with (TULNKID = "R-T01") and 2 non-target lesions/sites with TULNKID "(R-NT01" and ", R-NT02" ) identified at screening. " T01 " and " R-NT01 " are located in the "LIVER" liver, and " R-NT02 " is located in the "CHEST WALL"chest wall.

Dataset wrap
Nametu
Dataset2
RowSTUDYIDDOMAINUSUBJIDTUSEQTULNKIDTUTESTCDTUTESTTUORRESTUSTRESCTUNAMTULOCTUMETHODTUEVALTUEVALIDEPOCHVISITNUMVISITTUDTCTUDY
1EX01010TU900101R-T01TUMIDENTTumor IdentificationTARGETTARGETRADIOL. INC.LIVERCT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
2EX01010TU900102R-NT01TUMIDENTTumor IdentificationNON-TARGETNON-TARGETRADIOL. INC.LIVERCT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
3EX01010TU900103R-NT02TUMIDENTTumor IdentificationNON-TARGETNON-TARGETRADIOL. INC.CHEST WALLCT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2

4.10.3 TR Domain Model

The  tr.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in the TR domain1 in the TR domain. This example shows the data for one 1 subject collected at the screening, week 12, and subsequent 12-week follow-up visits.

This example shows the situation where the Independent Assessor independent assessor provided the summary values for Target target lesions as a group (TRGRPID = "TARGET"). The TRTESTCDs used for the assessments are: "SUMDIAM", "ACNSD", "PCBSD", and "PCNSD". Note that the sponsor sponsors should not derive these values if they were not part of the data capture or not provided in the transfer from the vendor.

Dataset wrap
Nametr
Rowcaps
Rows 1-4: Show the measurements of the " R-T01 " target tumor in the "LIVER" liver and the assessments of the 2 non-Target target lesions/sites " R-NT01 " and " R-NT02 " in the "LIVER" and "CHEST WALL" liver and chest wall at screening.
Rows 5-11: Show the measurement of the "R-T01" target tumor and the tumor states of "R-NT01" and "R-NT02" the non-targets at week 12. " R-T01 " shows a decrease from 17mm at baseline to 7mm, which is a Percent Change From Baseline in Sum of Diameter ( PCBSD ) of -59%. " R-NT01 " has a TUMSTATE = "ABSENT" and "R-NT02" has a TUMSTATE = "ENLARGEMENT FROM NADIR". 
Rows 12-18: Show the measurement of the " R-T01 " target tumor and the tumor states of "R-NT01" and "R-NT02" the non-targets at week 24. " R-T01 " is absent (LDIAM = "0"), which is a Percent Change From Baseline in Sum of Diameter ( PCBSD ) of -100%. " R-NT01 " remains TUMSTATE = "ABSENT" and " R-NT02 " has a TUMSTATE = "PRESENT".
Dataset2
RowSTUDYIDDOMAINUSUBJIDTRSEQTRGRPIDTRLNKGRPTRLNKIDTRTESTCDTRTESTTRORRESTRORRESUTRSTRESCTRSTRESNTRSTRESUTRNAMTRMETHODTREVALTREVALIDEPOCHVISITNUMVISITTRDTCTRDY
1EX01010TR900101TARGETR-A1R-T01LDIAMLongest Diameter17mm1717mmRADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
2EX01010TR900102TARGETR-A1
SUMDIAMSum of Diameter17mm1717mmRADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING

3EX01010TR900103NON-TARGETR-A1R-NT01TUMSTATETumor StatePRESENT
PRESENT

RADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
4EX01010TR900104NON-TARGETR-A1R-NT02TUMSTATETumor StatePRESENT
PRESENT

RADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTSCREEN10SCREENING2010-01-02-2
5EX01010TR900105TARGETR-R-A2R-T01LDIAMLongest Diameter7mm77mmRADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
6EX01010TR900106TARGETR-A2
SUMDIAMSum of Diameter7mm77mmRADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

7EX01010TR900107TARGETR-A2
ACNSDAbsolute Change From Nadir in Sum of Diameter-10mm-10-10mmRADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

8EX01010TR900108TARGETR-A2
PCBSDPercent Change From Baseline in Sum of Diameter-59%-59-59%RADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

9EX01010TR900109TARGETR-A2
PCNSDPercent Change From Nadir in Sum of Diameter-59%-59-59%RADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 12

10EX01010TR9001010NON-TARGETR-A2R-NT01TUMSTATETumor StateABSENT
ABSENT

RADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
11EX01010TR9001011NON-TARGETR-A2R-NT02TUMSTATETumor StateENLARGEMENT FROM NADIR
ENLARGEMENT FROM NADIR

RADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT20WEEK 122010-03-2985
12EX01010TR9001012TARGETR-A3R-T01LDIAMLongest Diameter0mm00mmRADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171
13EX01010TR9001013TARGETR-A3
SUMDIAMSum of Diameter0mm00mmRADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

14EX01010TR9001014TARGETR-A3
ACNSDAbsolute Change From Nadir in Sum of Diameter-17mm-17-17mmRADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

15EX01010TR9001015TARGETR-A3
PCBSDPercent Change From Baseline in Sum of Diameter-100%-100-100%RADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

16EX01010TR9001016TARGETR-A3
PCNSDPercent Change From Nadir in Sum of Diameter-100%-100-100%RADIOL. INC.
INDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 24

17EX01010TR9001017NON-TARGETR-A3R-NT01TUMSTATETumor StateABSENT
ABSENT

RADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171
18EX01010TR9001018NON-TARGETR-A3R-NT02TUMSTATETumor StatePRESENT
PRESENT

RADIOL. INC.CT SCANINDEPENDENT ASSESSORRADIOLOGISTTREATMENT30WEEK 242010-06-23171

...